Tenascin Expression in Ovarian Tumours
Author Information
Author(s): KE Wilson, SP Langdon, AM Lessells, WR Miller
Primary Institution: ICRF Medical Oncology Unit and Department of Pathology, Western General Hospital, Edinburgh, UK
Hypothesis
Malignant ovarian tumours have increased expression of tenascin compared with benign tumours.
Conclusion
Malignant ovarian tumours show increased stromal expression of tenascin and a different RNA splicing pattern compared to benign tumours.
Supporting Evidence
- Malignant and borderline tumours showed significantly greater incidence and intensity of stromal staining than benign tumours.
- 9 out of 12 malignant tumours showed increased expression of larger tenascin RNA isoforms compared to benign tumours.
Takeaway
This study looked at a protein called tenascin in ovarian tumours and found that it is more common in cancerous tumours than in non-cancerous ones.
Methodology
The study examined tenascin expression in 50 ovarian tumours using immunohistochemistry and RT-PCR.
Limitations
The study had small sample sizes for some subgroups, which may limit the generalizability of the findings.
Participant Demographics
32 malignant, 7 borderline, and 11 benign ovarian tumours from 50 patients.
Statistical Information
P-Value
0.043
Statistical Significance
p<0.0001
Want to read the original?
Access the complete publication on the publisher's website